Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (86) clinical trials

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

At this time there is no experience concerning the sequencing strategy when using the two effective therapeutical approaches as targeting the Ras/Raf signalling pathway by BRAF and MEK inhibition or targeting immunologic checkpoint control with an antiPD-L1 antibody. This is a prospective, open, multicenter, randomized phase II study in patients ...

Phase

Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases

Study Drug Administration: If you are found to be eligible to take part in this study, you will receive atezolizumab by vein over 30-60 minutes (+/-10-15 minutes). Bevacizumab will then be given by vein over 30, 60, or 90 minutes (+/-10-15 minutes). You may be given standard drugs to help ...

Phase

Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases

Study Procedure: You will receive SRS on Day 1. There will be 1 day of treatment. You will sign a separate consent form for SRS that will explain the procedure and risks in detail. Study Visits: At 1, 6, and 9 months (+/- 14 days) after Day 1, the following ...

Phase

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Primary Objective: To determine the irRECIST* response rate of pembrolizumab with ipilimumab following initial progression or stable disease to anti-PD1/L1 antibody (or combination not containing anti-CTLA4) in subjects with advanced melanoma. Secondary Objective To summarize the progression-free survival (RECIST v1.1 and irRC) of the combination following prior treatment with anti-PD1/L1 ...

Phase

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma Merkel Cell Carcinoma or Other Solid Tumors

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Phase

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body. Eligible participants include those who have not received any systemic ...

Phase

Fecal Microbiota Transplant (FMT) in Melanoma Patients

This is a phase II Simon two-stage single-center study of concurrent fecal microbiota transplang (FMT) with pembrolizumab in patients with PD-1 resistant/refractory melanoma. The study will be conducted over a 12-week period (and up to 24-weeks in responding patients). Patient eligibility is based upon prior exposure to PD-1 inhibitor therapy ...

Phase

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Phase

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases. All patients will receive vemurafenib 960 mg twice a day on days 1 - 28 combined with cobimetinib 60 mg once a day on days 1 - ...

Phase

Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma

This research study is a Phase II clinical trial. Researchers hope to study the effects of the combination of Nivolumab and Ipilimumab. Many cancers use specific pathways (such as PD-1/PD-L1 and CTLA-4) to evade the body's immune system. Nivolumab and ipilimumab work by blocking the PD-1/PD-L1 and CTLA-4 pathways and ...

Phase